Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Website related acquisitions and licensing for major media network
Represented major U.S. media network in numerous acquisitions and licensing of hardware, software and content to design, develop, host and operate more
Environmental compliance for multinational manufacturer
Represents a multinational manufacturer of chemicals, glass, fiberglass and coatings by providing environmental legal services. We provide more
Playboy Enterprises v. Dumas
Defended widow of artist Patrick Nagel in copyright infringement trial brought by publisher of Playboy magazine and succeeded in establishing her more
Leather Indus., et al. v. EPA
The firm served as lead counsel in representing the city of Pueblo, Colorado in a successful challenge to parts of an EPA rule on sludge handling more